China Resources Pharmaceutical Group Limited (Stock Code: 3320) has announced that its subsidiary, China Resources Sanjiu Medical & Pharmaceutical Company Limited (CR Sanjiu), published unaudited financial results for the nine months ended 30 September 2025. According to the announcement, CR Sanjiu is 63.22% indirectly owned by China Resources Pharmaceutical Group Limited and is listed on the Shenzhen Stock Exchange.

CR Sanjiu recorded revenue of RMB21,986,403,962.07 and net profit of RMB2,899,296,865.59 for the reporting period. A net decrease of RMB838,704,376.33 was reported in cash and cash equivalents, while the period-end figure for cash and cash equivalents stood at RMB4,022,463,617.09. By 30 September 2025, the company’s total assets reached RMB56,563,981,806.22, with total liabilities of RMB19,184,581,916.76 and owner’s equity of RMB37,379,399,889.46.

The financial figures released by CR Sanjiu were prepared in accordance with PRC Generally Accepted Accounting Principles and remain subject to auditing. The announcement reminds shareholders and potential investors that these data refer only to CR Sanjiu and do not represent the overall performance of the entire group. Further details can be found on the Shenzhen Stock Exchange website.